Century Therapeutics Past Earnings Performance
Past criteria checks 0/6
Century Therapeutics has been growing earnings at an average annual rate of 0.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 75.8% per year.
Key information
0.3%
Earnings growth rate
94.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 75.8% |
| Return on equity | -74.0% |
| Net Margin | -6,115.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06
Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25Revenue & Expenses BreakdownBeta
How Century Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -137 | 35 | 9 |
| 30 Sep 23 | 2 | -129 | 34 | 0 |
| 30 Jun 23 | 5 | -127 | 33 | 0 |
| 31 Mar 23 | 6 | -125 | 33 | 0 |
| 31 Dec 22 | 5 | -131 | 32 | 6 |
| 30 Sep 22 | 5 | -127 | 30 | 0 |
| 30 Jun 22 | 2 | -123 | 28 | 0 |
| 31 Mar 22 | 1 | -115 | 24 | 0 |
| 31 Dec 21 | 0 | -96 | 19 | 0 |
| 30 Sep 21 | 0 | -83 | 16 | 12 |
| 30 Jun 21 | 0 | -70 | 12 | 23 |
| 31 Mar 21 | 0 | -62 | 10 | 32 |
| 31 Dec 20 | 0 | -54 | 9 | 40 |
Quality Earnings: IPSC is currently unprofitable.
Growing Profit Margin: IPSC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IPSC is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.
Accelerating Growth: Unable to compare IPSC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IPSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: IPSC has a negative Return on Equity (-73.98%), as it is currently unprofitable.